TY - JOUR T1 - ELISA detection of SARS-CoV-2 antibodies in saliva JF - medRxiv DO - 10.1101/2020.08.17.20176594 SP - 2020.08.17.20176594 AU - Melanie A. MacMullan AU - Albina Ibrayeva AU - Kylie Trettner AU - Laura Deming AU - Sudipta Das AU - Frances Tran AU - Jose Ricardo Moreno AU - Joseph G. Casian AU - Prithivi Chellamuthu AU - Jeffrey Kraft AU - Kenneth Kozak AU - Fred E. Turner AU - Vladimir I. Slepnev AU - Lydia M. Le Page Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/21/2020.08.17.20176594.abstract N2 - To facilitate containment of the COVID-19 pandemic currently active in the United States and across the world, options for easy, non-invasive antibody testing are required. Here we have adapted a commercially available, serum-based ELISA for use with saliva samples, which will enable widespread, affordable testing for patients who experienced this disease.Competing Interest StatementAll authors are, or were at the time of research, employed by Curative Inc, a COVID-19 diagnostics company. L.D., F.E.T. and V.S have partial ownership of Curative Inc.Funding StatementNo funding was received external to Curative Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Clinical samples were collected under UCLA Institutional Review Board approved study protocol IRB#20-000703.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the authors upon reasonable request. ER -